Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers

Behavioural Pharmacology

Volumn 17, Issue 8, 2006, Pages 731-735

  Sofuoglu, Mehmet ^a,c   Mouratidis, Maria ^b   Yoo, Sonah ^a   Kosten, Thomas ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

adrenergic antagonist; adrenergic antagonist; Carvedilol; Human; Nicotine

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NICOTINE; PLACEBO;

ABSTINENCE; ARTICLE; ATTENUATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYMPTOM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EXPERIMENT; FEMALE; HEART RATE VARIABILITY; HEARTBURN; HICCUP; HUMAN; LOZENGE; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SMOKING; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADRENERGIC ANTAGONISTS; ADULT; BLOOD PRESSURE; CARBAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GANGLIONIC STIMULANTS; HEART RATE; HUMANS; MALE; NICOTINE; PROPANOLAMINES; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 33751162405     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32801155d4     Document Type: Article

References (17)

1. Benowitz NL, Gourlay SG (1997). Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 29:1422-1431.
2. Brauer LH, Cramblett MJ, Paxton DA, Rose JE (2001). Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology 159:31-37.
3. Chausmer AL, Smith BJ, Kelly RY, Griffiths RR (2003). Cocaine-like subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166). Behav Pharmacol 14:111-120.
4. Choi JH, Dresler CM, Norton MR, Strahs KR (2003). Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 5:635-644.
5. Dunn CJ, Lea AP, Wagstaff AJ (1997). Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 54:161-185.
6. Frishman WH (1998). Carvedilol. N Engl J Med 339:1759-1765.
7. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. (1996). Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94:2817-2825.
8. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991). The Fagerstrom Test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addictions 86:1119-1127.
9. Herman RB, Jesudason PJ, Mustafa AM, Husain R, Choy AM, Lang CC (2003). Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol 55:134-138.
10. Houtsmuller EJ, Henningfield JE, Stitzer ML (2003). Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology (Berlin) 167:20-27.
11. Hughes JR, Hatsukami D (1986). Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289-294.
12. Laviolette SR, van der Kooy D (2003). Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psychiatry 8:50-59.
13. McNair D, Lorr M, Dropperman L (1971). Manual for profile of mood states. San Diego: Educational and industrial testing services.
14. Morgan T (1994). Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clinical Pharmacokinetics 26:335-346.
15. Reeves D, Winter K, Kane R, Elsmore T, Bleiberg J (2002). ANAM 2001 User's Manual, National Cognitive Recovery Foundation.
16. Sofuoglu M, Babb D, Hatsukami DK (2003). Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine Tob Res 5:947-953.
17. Watson D, Clark LA, Tellegen A (1988). Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063-1070.